{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T06:44:05Z","timestamp":1793169845039,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008212","name":"Drexel University College of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008212","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Otolaryngology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.amjoto.2022.103576","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T11:24:59Z","timestamp":1659698699000},"page":"103576","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Use of biologics for treatment of autoimmune inner ear disease"],"prefix":"10.1016","volume":"43","author":[{"given":"Bailey","family":"Balouch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Meehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishwarya","family":"Suresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haniah A.","family":"Zaheer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdur Rahman","family":"Jabir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas M.","family":"Qatanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Suresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2426-2593","authenticated-orcid":false,"given":"Syed Z.","family":"Kaleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"McKinnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjoto.2022.103576_bb0005","doi-asserted-by":"crossref","DOI":"10.1177\/2058738418808680","article-title":"Autoimmune inner ear disease (AIED): a diagnostic challenge","volume":"32","author":"Ciorba","year":"2018","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"5","key":"10.1016\/j.amjoto.2022.103576_bb0010","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/lio2.28","article-title":"AAO: autoimmune and autoinflammatory (disease) in otology: what is new in immune-mediated hearing loss","volume":"1","author":"Vambutas","year":"2016","journal-title":"Laryngoscope Investig Otolaryngol"},{"key":"10.1016\/j.amjoto.2022.103576_bb0015","series-title":"CURRENT diagnosis & treatment: rheumatology","article-title":"Chapter 68. Sensorineural hearing loss (immune-mediated inner ear disease)","author":"Stone","year":"2013"},{"issue":"9","key":"10.1016\/j.amjoto.2022.103576_bb0020","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1172\/JCI76503","article-title":"Early efficacy trial of anakinra in corticosteroid-resistant autoimmune inner ear disease","volume":"124","author":"Vambutas","year":"2014","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.amjoto.2022.103576_bb0025","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/lio2.205","article-title":"Emerging options in immune-mediated hearing loss","volume":"4","author":"Sakano","year":"2019","journal-title":"Laryngoscope Investig Otolaryngol"},{"issue":"20","key":"10.1016\/j.amjoto.2022.103576_bb0030","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1001\/jama.2011.679","article-title":"Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial","volume":"305","author":"Rauch","year":"2011","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.amjoto.2022.103576_bb0035","first-page":"196","article-title":"Autoimmune inner ear disease: therapy","volume":"10","author":"McCabe","year":"1989","journal-title":"Am J Otol"},{"issue":"4","key":"10.1016\/j.amjoto.2022.103576_bb0040","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000351289","article-title":"Autoimmune inner ear disease: a retrospective review of forty-seven patients","volume":"18","author":"Matsuoka","year":"2013","journal-title":"Audiol Neurootol"},{"issue":"2","key":"10.1016\/j.amjoto.2022.103576_bb0045","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.semarthrit.2004.07.001","article-title":"Immune-mediated inner ear disease: 10-year experience","volume":"34","author":"Broughton","year":"2004","journal-title":"Semin Arthritis Rheum"},{"issue":"8 Pt 1","key":"10.1016\/j.amjoto.2022.103576_bb0050","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1288\/00005537-199408000-00004","article-title":"Methotrexate therapy for autoimmune hearing loss: a preliminary report","volume":"104","author":"Sismanis","year":"1994","journal-title":"Laryngoscope"},{"issue":"2","key":"10.1016\/j.amjoto.2022.103576_bb0055","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/1529-0131(200104)45:2<146::AID-ANR167>3.0.CO;2-I","article-title":"Open trial of methotrexate as treatment for autoimmune hearing loss","volume":"45","author":"Matteson","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.amjoto.2022.103576_bb0060","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/030006059302100404","article-title":"Azathioprine in combination with steroids in the treatment of autoimmune inner-ear disease","volume":"21","author":"Sara\u00e7aydin","year":"1993","journal-title":"J Int Med Res"},{"issue":"10","key":"10.1016\/j.amjoto.2022.103576_bb0065","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/j.ijporl.2009.06.025","article-title":"Mycophenolate mofetil as a treatment of steroid dependent Cogan's syndrome in childhood","volume":"73","author":"Hautefort","year":"2009","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"5","key":"10.1016\/j.amjoto.2022.103576_bb0070","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/01.mao.0000185082.28598.87","article-title":"Etanercept treatment for autoimmune inner ear disease: results of a pilot placebo-controlled study","volume":"26","author":"Cohen","year":"2005","journal-title":"Otol Neurotol"},{"issue":"5","key":"10.1016\/j.amjoto.2022.103576_bb0075","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/00129492-200109000-00010","article-title":"Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study","volume":"22","author":"Rahman","year":"2001","journal-title":"Otol Neurotol"},{"issue":"6","key":"10.1016\/j.amjoto.2022.103576_bb0080","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1159\/000095897","article-title":"Local perfusion of the tumor necrosis factor alpha blocker infliximab to the inner ear improves autoimmune neurosensory hearing loss","volume":"11","author":"Van Wijk","year":"2006","journal-title":"Audiol Neurootol"},{"issue":"2","key":"10.1016\/j.amjoto.2022.103576_bb0085","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00405-019-05716-x","article-title":"Intratympanic infliximab is a safe and effective rescue therapy for refractory immune-mediated hearing loss","volume":"277","author":"Mata-Castro","year":"2020","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"1","key":"10.1016\/j.amjoto.2022.103576_bb0090","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/014556131109000107","article-title":"Treatment-refractory autoimmune sensorineural hearing loss: response to infliximab","volume":"90","author":"Liu","year":"2011","journal-title":"Ear Nose Throat J"},{"issue":"10","key":"10.1016\/j.amjoto.2022.103576_bb0095","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s10067-014-2625-z","article-title":"Infliximab has no apparent effect in the inner ear hearing function of patients with rheumatoid arthritis and ankylosing spondylitis","volume":"33","author":"Toktas","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"9","key":"10.1016\/j.amjoto.2022.103576_bb0100","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1097\/MAO.0000000000000566","article-title":"An open label study to evaluate the safety and efficacy of intratympanic golimumab therapy in patients with autoimmune inner ear disease","volume":"35","author":"Derebery","year":"2014","journal-title":"Otol Neurotol"},{"issue":"4","key":"10.1016\/j.amjoto.2022.103576_bb0105","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000320606","article-title":"A pilot study of rituximab in immune-mediated inner ear disease","volume":"16","author":"Cohen","year":"2011","journal-title":"Audiol Neurootol"},{"issue":"1","key":"10.1016\/j.amjoto.2022.103576_bb0110","doi-asserted-by":"crossref","first-page":"55","DOI":"10.7874\/jao.2016.20.1.55","article-title":"Refractory granulomatosis with polyangiitis presenting as facial paralysis and bilateral sudden deafness","volume":"20","author":"Kim","year":"2016","journal-title":"J Audiol Otol"},{"issue":"3","key":"10.1016\/j.amjoto.2022.103576_bb0115","doi-asserted-by":"crossref","first-page":"R64","DOI":"10.1186\/ar4237","article-title":"Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens","volume":"15","author":"Kuemmerle-Deschner","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.amjoto.2022.103576_bb0120","article-title":"Laryngeal applications of platelet rich plasma and platelet poor plasma: a systematic review","author":"Suresh","year":"2021","journal-title":"J Voice"},{"key":"10.1016\/j.amjoto.2022.103576_bb0125","series-title":"Joanna Briggs Institute reviewer\u2019s manual","article-title":"Chapter 3: systematic reviews of effectiveness","author":"Tufanaru","year":"2017"},{"key":"10.1016\/j.amjoto.2022.103576_bb0130","series-title":"JBI manual for evidence synthesis","article-title":"Chapter 7: systematic reviews of etiology and risk","author":"Moola","year":"2020"},{"issue":"8","key":"10.1016\/j.amjoto.2022.103576_bb0135","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3109\/14992027.2013.790564","article-title":"TNF-alpha inhibition using etanercept prevents noise-induced hearing loss by improvement of cochlear blood flow in vivo","volume":"52","author":"Arpornchayanon","year":"2013","journal-title":"Int J Audiol"},{"issue":"7","key":"10.1016\/j.amjoto.2022.103576_bb0140","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1097\/MAO.0000000000001095","article-title":"Tumor necrosis factor-induced decrease of cochlear blood flow can be reversed by etanercept or JTE-013","volume":"37","author":"Sharaf","year":"2016","journal-title":"Otol Neurotol"},{"key":"10.1016\/j.amjoto.2022.103576_bb0145","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3389\/fphar.2014.00287","article-title":"Inflammatory and immune responses in the cochlea: potential therapeutic targets for sensorineural hearing loss","volume":"5","author":"Fujioka","year":"2014","journal-title":"Front Pharmacol"},{"issue":"11","key":"10.1016\/j.amjoto.2022.103576_bb0150","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1161\/STROKEAHA.110.593327","article-title":"Tumor necrosis factor-alpha enhances microvascular tone and reduces blood flow in the cochlea via enhanced sphingosine-1-phosphate signaling","volume":"41","author":"Scherer","year":"2010","journal-title":"Stroke"},{"issue":"482","key":"10.1016\/j.amjoto.2022.103576_bb0155","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao0935","article-title":"Delivery of therapeutics to the inner ear: the challenge of the blood-labyrinth barrier","volume":"11","author":"Nyberg","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.amjoto.2022.103576_bb0160","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.3389\/fneur.2019.01353","article-title":"Intracochlear perfusion of tumor necrosis factor-alpha induces sensorineural hearing loss and synaptic degeneration in Guinea pigs","volume":"10","author":"Katsumi","year":"2019","journal-title":"Front Neurol"},{"issue":"6","key":"10.1016\/j.amjoto.2022.103576_bb0165","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1097\/MAO.0b013e31818256a9","article-title":"Tumor necrosis factor alpha can induce recruitment of inflammatory cells to the cochlea","volume":"29","author":"Keithley","year":"2008","journal-title":"Otol Neurotol"},{"issue":"7","key":"10.1016\/j.amjoto.2022.103576_bb0170","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/lary.23907","article-title":"Blood levels of TNF-alpha, IL-10, and IL-12 in idiopathic sudden sensorineural hearing loss","volume":"123","author":"Demirhan","year":"2013","journal-title":"Laryngoscope"},{"issue":"10","key":"10.1016\/j.amjoto.2022.103576_bb0175","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1097\/MAO.0000000000001523","article-title":"Cochlear pericytes are capable of reversibly decreasing capillary diameter in vivo after tumor necrosis factor exposure","volume":"38","author":"Bertlich","year":"2017","journal-title":"Otol Neurotol"},{"key":"10.1016\/j.amjoto.2022.103576_bb0180","series-title":"StatPearls","article-title":"Etanercept","author":"Pan","year":"2022"},{"issue":"3","key":"10.1016\/j.amjoto.2022.103576_bb0185","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/art.21179","article-title":"Etanercept therapy for immune-mediated cochleovestibular disorders: a multi-center, open-label, pilot study","volume":"53","author":"Matteson","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.amjoto.2022.103576_bb0190","series-title":"StatPearls","article-title":"Infliximab-abda","author":"Aboobacker","year":"2022"},{"key":"10.1016\/j.amjoto.2022.103576_bb0195","series-title":"StatPearls","article-title":"Adalimumab","author":"Ellis","year":"2022"},{"issue":"5","key":"10.1016\/j.amjoto.2022.103576_bb0200","doi-asserted-by":"crossref","first-page":"422","DOI":"10.4161\/mabs.1.5.9286","article-title":"Golimumab","volume":"1","author":"Mazumdar","year":"2009","journal-title":"MAbs"},{"issue":"5","key":"10.1016\/j.amjoto.2022.103576_bb0205","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/coa.12432","article-title":"Current understanding of the pathogenesis of autoimmune inner ear disease: a review","volume":"40","author":"Goodall","year":"2015","journal-title":"Clin Otolaryngol"},{"issue":"2","key":"10.1016\/j.amjoto.2022.103576_bb0210","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/MAO.0b013e318241b548","article-title":"Temporal bone histopathology and immunoglobulin deposition in Sjogren's syndrome","volume":"33","author":"Calzada","year":"2012","journal-title":"Otol Neurotol"},{"issue":"12","key":"10.1016\/j.amjoto.2022.103576_bb0215","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1172\/JCI70972","article-title":"The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging","volume":"123","author":"Montalvao","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjoto.2022.103576_bb0220","series-title":"StatPearls","article-title":"Rituximab","author":"Hanif","year":"2022"},{"issue":"8","key":"10.1016\/j.amjoto.2022.103576_bb0225","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"10.1016\/j.amjoto.2022.103576_bb0230","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1097\/00005537-200209000-00019","article-title":"Tumor necrosis factor-alpha, an initiator, and etanercept, an inhibitor of cochlear inflammation","volume":"112","author":"Satoh","year":"2002","journal-title":"Laryngoscope"},{"issue":"1","key":"10.1016\/j.amjoto.2022.103576_bb0235","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000082306","article-title":"Innate immunity contributes to cochlear adaptive immune responses","volume":"10","author":"Hashimoto","year":"2005","journal-title":"Audiol Neurootol"},{"issue":"3","key":"10.1016\/j.amjoto.2022.103576_bb0240","first-page":"308","article-title":"Changes in proinflammatory cytokines in the cochlea in relation to hearing thresholds in noise-exposed rats","volume":"13","author":"Arslan","year":"2017","journal-title":"J Int Adv Otol"},{"issue":"3","key":"10.1016\/j.amjoto.2022.103576_bb0245","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.4049\/jimmunol.1002275","article-title":"IL-1beta is overexpressed and aberrantly regulated in corticosteroid nonresponders with autoimmune inner ear disease","volume":"186","author":"Pathak","year":"2011","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.amjoto.2022.103576_bb0250","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.3892\/mmr.2017.6784","article-title":"Matrix metalloproteinase-2 and -9 contribute to functional integrity and noise-induced damage to the blood-labyrinth-barrier","volume":"16","author":"Wu","year":"2017","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.amjoto.2022.103576_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijporl.2019.109656","article-title":"Lipopolysaccharide disrupts the cochlear blood-labyrinth barrier by activating perivascular resident macrophages and up-regulating MMP-9","volume":"127","author":"Jiang","year":"2019","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"5","key":"10.1016\/j.amjoto.2022.103576_bb0260","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.lpm.2009.01.012","article-title":"Indications of anakinra","volume":"38","author":"Chauffier","year":"2009","journal-title":"Presse Med"},{"issue":"1","key":"10.1016\/j.amjoto.2022.103576_bb0265","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12969-015-0041-9","article-title":"Early detection of sensorineural hearing loss in Muckle-Wells-syndrome","volume":"13","author":"Kuemmerle-Deschner","year":"2015","journal-title":"Pediatr Rheumatol Online J"},{"issue":"37","key":"10.1016\/j.amjoto.2022.103576_bb0270","doi-asserted-by":"crossref","first-page":"E7766","DOI":"10.1073\/pnas.1702946114","article-title":"NLRP3 mutation and cochlear autoinflammation cause syndromic and nonsyndromic hearing loss DFNA34 responsive to anakinra therapy","volume":"114","author":"Nakanishi","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.amjoto.2022.103576_bb0275","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1002\/art.40208","article-title":"Clinical and molecular phenotypes of low-penetrance variants of NLRP3: diagnostic and therapeutic challenges","volume":"69","author":"Kuemmerle-Deschner","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.amjoto.2022.103576_bb0280","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/art.37810","article-title":"Hearing loss in Muckle-Wells syndrome","volume":"65","author":"Kuemmerle-Deschner","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.amjoto.2022.103576_bb0285","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/art.30149","article-title":"Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome","volume":"63","author":"Kuemmerle-Deschner","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.amjoto.2022.103576_bb0290","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1002\/art.34409","article-title":"Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes","volume":"64","author":"Sibley","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.amjoto.2022.103576_bb0295","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.25057","article-title":"Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease\/chronic infantile neurologic, cutaneous, articular syndrome","volume":"62","author":"Neven","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.amjoto.2022.103576_bb0300","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJMoa055137","article-title":"Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition","volume":"355","author":"Goldbach-Mansky","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjoto.2022.103576_bb0305","series-title":"Canakinumab (Ilaris)","article-title":"CADTH common drug reviews","year":"2016"},{"issue":"5","key":"10.1016\/j.amjoto.2022.103576_bb0310","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1097\/01.mao.0000185081.28598.5c","article-title":"Serial audiometry in a clinical trial of AIED treatment","volume":"26","author":"Niparko","year":"2005","journal-title":"Otol Neurotol"},{"issue":"10","key":"10.1016\/j.amjoto.2022.103576_bb0315","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1177\/1060028020908067","article-title":"Effectiveness of steroid treatment for sudden sensorineural hearing loss: a meta-analysis of randomized controlled trials","volume":"54","author":"Li","year":"2020","journal-title":"Ann Pharmacother"},{"issue":"6","key":"10.1016\/j.amjoto.2022.103576_bb0320","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/lio2.508","article-title":"Autoimmune inner ear disease: a systematic review of management","volume":"5","author":"Breslin","year":"2020","journal-title":"Laryngoscope Investig Otolaryngol"},{"issue":"4","key":"10.1016\/j.amjoto.2022.103576_bb0325","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/MAO.0b013e3181a52773","article-title":"Safety of high-dose corticosteroids for the treatment of autoimmune inner ear disease","volume":"30","author":"Alexander","year":"2009","journal-title":"Otol Neurotol"},{"issue":"12","key":"10.1016\/j.amjoto.2022.103576_bb0330","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1136\/ard.2005.038349","article-title":"A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs","volume":"65","author":"Klareskog","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.amjoto.2022.103576_bb0335","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/jcph.1348","article-title":"The safety profile of tumor necrosis factor inhibitors in ankylosing spondylitis: are TNF inhibitors safer than we thought?","volume":"59","author":"Wro\u0144ski","year":"2019","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.amjoto.2022.103576_bb0340","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"}],"container-title":["American Journal of Otolaryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196070922002034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196070922002034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T05:11:33Z","timestamp":1759295493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196070922002034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0196070922002034"],"URL":"https:\/\/doi.org\/10.1016\/j.amjoto.2022.103576","relation":{},"ISSN":["0196-0709"],"issn-type":[{"value":"0196-0709","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of biologics for treatment of autoimmune inner ear disease","name":"articletitle","label":"Article Title"},{"value":"American Journal of Otolaryngology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjoto.2022.103576","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103576"}}